639048-45-6
Chemical Structure
KKL-55
- CAS No.: 639048-45-6
- Formula:C11H12ClN5O
- Molecular Weight:265.70
InChIKey: IBRCUOMIAFDQTM-UHFFFAOYSA-N
SMILES: O=C(C1=CC(Cl)=CC=C1)NC2=NN=NN2CCC
Biological Activity: KKL-55 is a broad-spectrum antibacterial agent that inhibits the trans-translation pathway and the ClpXP protease. KKL-55 suppresses trans-translation of non-stop mRNA, interferes with the binding of EF-Tu to tmRNA, and inhibits the proteolysis of substrates by ClpXP. KKL-55 blocks spore germination of Bacillus anthracis and protects macrophages from damage induced by anthrax toxin. By virtue of its inhibitory effect on ClpXP, KKL-55 synergistically enhances the antibacterial activity of antibiotics against drug-resistant Staphylococcus aureus. KKL-55 can be used in studies related to bacterial infections[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KKL-55 | KKL-55 is a broad-spectrum antibacterial agent that inhibits the trans-translation pathway and the ClpXP protease. KKL-55 suppresses trans-translation of non-stop mRNA, interferes with the binding of EF-Tu to tmRNA, and inhibits the proteolysis of substrates by ClpXP. KKL-55 blocks spore germination of Bacillus anthracis and protects macrophages from damage induced by anthrax toxin. By virtue of its inhibitory effect on ClpXP, KKL-55 synergistically enhances the antibacterial activity of antibiotics against drug-resistant Staphylococcus aureus. KKL-55 can be used in studies related to bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Alumasa JN, et al. Tetrazole-Based trans-Translation Inhibitors Kill Bacillus anthracis Spores To Protect Host Cells. Antimicrob Agents Chemother. 2017;61(10):e01199-17. Published 2017 Sep 22. [Content Brief]
- [2]. Varshney, et al. A trans -translation inhibitor kills Mycobacterium tuberculosis by targeting ribosomal protein bL12. bioRxiv [Preprint]. 2025 Jun 2:2025.06.02.656638.
- [3]. Ramadoss NS. The trans-translation pathway as a target for broad-spectrum antibacterial development. 2013.
